MicroRNA targeting to modulate tumor microenvironment

Frontiers in Oncology

Volumn 6, Issue JAN, 2016, Pages

  Kuninty, Praneeth R ^a   Schnittert, Jonas ^a   Storm, Gert ^a,b   Prakash, Jai ^a  

^a UNIVERSITY OF TWENTE   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Cancer associated fibroblasts; Gene delivery; MicroRNA; Tumor microenvironment; Tumor stroma; Tumor associated macrophages

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; MICRORNA; MICRORNA 101; MICRORNA 141; MICRORNA 155; MICRORNA 16; MICRORNA 200; MICRORNA 205; MICRORNA 21; MICRORNA 214; MICRORNA 31; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNTRANSLATED RNA; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CELL DIFFERENTIATION; CELL INTERACTION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; DRUG DELIVERY SYSTEM; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; HUMAN; IMMUNOGENICITY; MACROPHAGE; METASTASIS; MICROARRAY ANALYSIS; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA TRANSLATION; STROMA CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 84958166810     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2016.00003     Document Type: Article

References (78)

1. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell (2012) 21:309-22. doi:10.1016/j.ccr.2012.02.022
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144:646-74. doi:10.1016/j.cell.2011.02.013
3. Mueller MM, Fusenig NE. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer (2004) 4:839-49. doi:10.1038/nrc1477
4. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med (2013) 19:1423-37. doi:10.1038/nm.3394
5. Suzuki HI, Katsura A, Matsuyama H, Miyazono K. MicroRNA regulons in tumor microenvironment. Oncogene (2015) 34:3085-94. doi:10.1038/onc.2014.254
6. Melo SA, Kalluri R. Molecular pathways: microRNAs as cancer therapeutics. Clin Cancer Res (2012) 18:4234-9. doi:10.1158/1078-0432.CCR-11-2010
7. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer (2006) 6:259-69. doi:10.1038/nrc1840
8. Bader AG, Brown D, Stoudemire J, Lammers P. Developing therapeutic microRNAs for cancer. Gene Ther (2011) 18:1121-6. doi:10.1038/gt.2011.79
9. Mitra AK, Zillhardt M, Hua Y, Tiwari P, Murmann AE, Peter ME, et al. MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Cancer Discov (2012) 2:1100-8. doi:10.1158/2159-8290.CD-12-0206
10. Aprelikova O, Yu X, Palla J, Wei BR, John S, Yi M, et al. The role of miR-31 and its target gene SATB2 in cancer-associated fibroblasts. Cell Cycle (2010) 9:4387-98. doi:10.4161/cc.9.21.13674
11. Aprelikova O, Palla J, Hibler B, Yu X, Greer YE, Yi M, et al. Silencing of miR-148a in cancer-associated fibroblasts results in WNT10B-mediated stimulation of tumor cell motility. Oncogene (2013) 32:3246-53. doi:10.1038/onc.2012.351
12. Musumeci M, Coppola V, Addario A, Patrizii M, Maugeri-Saccà M, Memeo L, et al. Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene (2011) 30:4231-42. doi:10.1038/onc.2011.140
13. Bronisz A, Godlewski J, Wallace JA, Merchant AS, Nowicki MO, Mathsyaraja H, et al. Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol (2012) 14:159-67. doi:10.1038/ncb2396
14. Yang TS, Yang XH, Chen X, Wang XD, Hua J, Zhou DL, et al. MicroRNA-106b in cancer-associated fibroblasts from gastric cancer promotes cell migration and invasion by targeting PTEN. FEBS Lett (2014) 588:2162-9. doi:10.1016/j.febslet.2014.04.050
15. Tang X, Hou Y, Yang G, Wang X, Tang S, Du YE, et al. Stromal miR-200s contribute to breast cancer cell invasion through CAF activation and ECM remodeling. Cell Death Differ (2015) 23(1):132-45. doi:10.1038/cdd.2015.78
16. Li P, Shan JX, Chen XH, Zhang D, Su LP, Huang XY, et al. Epigenetic silencing of microRNA-149 in cancer-associated fibroblasts mediates prostaglandin E2/interleukin-6 signaling in the tumor microenvironment. Cell Res (2015) 25:588-603. doi:10.1038/cr.2015.51
17. Bullock MD, Pickard KM, Nielsen BS, Sayan AE, Jenei V, Mellone M, et al. Pleiotropic actions of miR-21 highlight the critical role of deregulated stromal microRNAs during colorectal cancer progression. Cell Death Dis (2013) 4:e684. doi:10.1038/cddis.2013.213
18. He M, Xu Z, Ding T, Kuang DM, Zheng L. MicroRNA-155 regulates inflammatory cytokine production in tumor-associated macrophages via targeting C/EBPbeta. Cell Mol Immunol (2009) 6:343-52. doi:10.1038/cmi.2009.45
19. Squadrito ML, Pucci F, Magri L, Moi D, Gilfillan GD, Ranghetti A, et al. miR-511-3p modulates genetic programs of tumor-associated macrophages. Cell Rep (2012) 1:141-54. doi:10.1016/j.celrep.2011.12.005
20. Chai ZT, Zhu XD, Ao JY, Wang WQ, Gao DM, Kong J, et al. microRNA-26a suppresses recruitment of macrophages by down-regulating macrophage colony-stimulating factor expression through the PI3K/Akt pathway in hepatocellular carcinoma. J Hematol Oncol (2015) 8:56. doi:10.1186/s13045-015-0150-4
21. Yang P, Li QJ, Feng Y, Zhang Y, Markowitz GJ, Ning S, et al. TGF-beta-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell (2012) 22:291-303. doi:10.1016/j.ccr.2012.07.023
22. Gaziel-Sovran A, Segura MF, Di Micco R, Collins MK, Hanniford D, Vega-Saenz de Miera E, et al. miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell (2011) 20:104-18. doi:10.1016/j.ccr.2011.05.027
23. Bezman NA, Chakraborty T, Bender T, Lanier LL. miR-150 regulates the development of NK and iNKT cells. J Exp Med (2011) 208:2717-31. doi:10.1084/jem.20111386
24. Trotta R, Chen L, Ciarlariello D, Josyula S, Mao C, Costinean S, et al. miR-155 regulates IFN-gamma production in natural killer cells. Blood (2012) 119:3478-85. doi:10.1182/blood-2011-12-398099
25. Chan YC, Khanna S, Roy S, Sen CK. miR-200b targets Ets-1 and is down-regulated by hypoxia to induce angiogenic response of endothelial cells. J Biol Chem (2011) 286:2047-56. doi:10.1074/jbc. M110.158790
26. Hu Y, Deng F, Song J, Lin J, Li X, Tang Y, et al. Evaluation of miR-29c inhibits endotheliocyte migration and angiogenesis of human endothelial cells by suppressing the insulin like growth factor 1. Am J Transl Res (2015) 7:866-77.
27. Babae N, Bourajjaj M, Liu Y, Van Beijnum JR, Cerisoli F, Scaria PV, et al. Systemic miRNA-7 delivery inhibits tumor angiogenesis and growth in murine xenograft glioblastoma. Oncotarget (2014) 5:6687-700. doi:10.18632/oncotarget.2235
28. Kong W, He L, Richards EJ, Challa S, Xu CX, Permuth-Wey J, et al. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene (2014) 33:679-89. doi:10.1038/onc.2012.636
29. Truettner JS, Katyshev V, Esen-Bilgin N, Dietrich WD, Dore-Duffy P. Hypoxia alters microRNA expression in rat cortical pericytes. Microrna (2013) 2:32-44. doi:10.2174/2211536611302010005
30. Adegboyega PA, Mifflin RC, DiMari JF, Saada JI, Powell DW. Immunohistochemical study of myofibroblasts in normal colonic mucosa, hyperplastic polyps, and adenomatous colorectal polyps. Arch Pathol Lab Med (2002) 126:829-36.
31. De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol (2003) 200:429-47. doi:10.1002/path.1398
32. Ishii G, Ochiai A, Neri S. Phenotypic and functional heterogeneity of cancer-associated fibroblast within the tumor microenvironment. Adv Drug Deliv Rev (2015). doi:10.1016/j.addr.2015.07.007
33. Madar S, Goldstein I, Rotter V. 'Cancer associated fibroblasts'-more than meets the eye. Trends Mol Med (2013) 19:447-53. doi:10.1016/j.molmed.2013.05.004
34. Xing F, Saidou J, Watabe K. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci (Landmark Ed) (2010) 15:166-79. doi:10.2741/3613
35. Strell C, Rundqvist H, Ostman A. Fibroblasts-a key host cell type in tumor initiation, progression, and metastasis. Ups J Med Sci (2012) 117:187-95. doi:10.3109/03009734.2012.654859
36. Aprelikova O, Green JE. MicroRNA regulation in cancer-associated fibroblasts. Cancer Immunol Immunother (2012) 61:231-7. doi:10.1007/s00262-011-1139-7
37. Yao Q, Cao S, Li C, Mengesha A, Kong B, Wei M. Micro-RNA-21 regulates TGF-beta-induced myofibroblast differentiation by targeting PDCD4 in tumor-stroma interaction. Int J Cancer (2011) 128:1783-92. doi:10.1002/ijc.25506
38. Ali S, Suresh R, Banerjee S, Bao B, Xu Z, Wilson J, et al. Contribution of microRNAs in understanding the pancreatic tumor microenvironment involving cancer associated stellate and fibroblast cells. Am J Cancer Res (2015) 5:1251-64.
39. Kadera BE, Li L, Toste PA, Wu N, Adams C, Dawson DW, et al. MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis. PLoS One (2013) 8:e71978. doi:10.1371/journal.pone.0071978
40. Li Q, Zhang D, Wang Y, Sun P, Hou X, Larner J, et al. MiR-21/Smad 7 signaling determines TGF-beta1-induced CAF formation. Sci Rep (2013) 3:2038. doi:10.1038/srep02038
41. Zhao L, Sun Y, Hou Y, Peng Q, Wang L, Luo H, et al. MiRNA expression analysis of cancer-associated fibroblasts and normal fibroblasts in breast cancer. Int J Biochem Cell Biol (2012) 44:2051-9. doi:10.1016/j.biocel.2012.08.005
42. Verghese ET, Drury R, Green CA, Holliday DL, Lu X, Nash C, et al. MiR-26b is down-regulated in carcinoma-associated fibroblasts from ER-positive breast cancers leading to enhanced cell migration and invasion. J Pathol (2013) 231:388-99. doi:10.1002/path.4248
43. Fang H, Declerck YA. Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res (2013) 73:4965-77. doi:10.1158/0008-5472.CAN-13-0661
44. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer (2006) 6:24-37. doi:10.1038/nrc1782
45. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell (2010) 141:39-51. doi:10.1016/j.cell.2010.03.014
46. Chanmee T, Ontong P, Konno K, Itano N. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers (Basel) (2014) 6:1670-90. doi:10.3390/cancers6031670
47. Squadrito ML, Etzrodt M, De Palma M, Pittet MJ. MicroRNA-mediated control of macrophages and its implications for cancer. Trends Immunol (2013) 34:350-9. doi:10.1016/j.it.2013.02.003
48. GraffJW, Dickson AM, Clay G, McCaffrey AP, Wilson ME. Identifying functional microRNAs in macrophages with polarized phenotypes. J Biol Chem (2012) 287:21816-25. doi:10.1074/jbc. M111.327031
49. Martinez-Pomares L. The mannose receptor. J Leukoc Biol (2012) 92:1177-86. doi:10.1189/jlb.0512231
50. Cai X, Yin Y, Li N, Zhu D, Zhang J, Zhang CY, et al. Re-polarization of tumor-associated macrophages to pro-inflammatory M1 macrophages by microRNA-155. J Mol Cell Biol (2012) 4:341-3. doi:10.1093/jmcb/mjs044
51. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12:253-68. doi:10.1038/nri3175
52. Li L, Zhang J, Diao W, Wang D, Wei Y, Zhang CY, et al. MicroRNA-155 and microRNA-21 promote the expansion of functional myeloid-derived suppressor cells. J Immunol (2014) 192:1034-43. doi:10.4049/jimmunol.1301309
53. Yamamoto S, Niida S, Azuma E, Yanagibashi T, Muramatsu M, Huang TT, et al. Inflammation-induced endothelial cell-derived extracellular vesicles modulate the cellular status of pericytes. Sci Rep (2015) 5:8505. doi:10.1038/srep08505
54. Lim PK, Bliss SA, Patel SA, Taborga M, Dave MA, Gregory LA, et al. Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Res (2011) 71:1550-60. doi:10.1158/0008-5472.CAN-10-2372
55. Brink PR, Valiunas V, Gordon C, Rosen MR, Cohen IS. Can gap junctions deliver? Biochim Biophys Acta (2012) 1818:2076-81. doi:10.1016/j.bbamem.2011.09.025
56. Wang J, Lu Z, Wientjes MG, Au JL. Delivery of siRNA therapeutics: barriers and carriers. AAPS J (2010) 12:492-503. doi:10.1208/s12248-010-9210-4
57. Gandhi NS, Tekade RK, Chougule MB. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. J Control Release (2014) 194:238-56. doi:10.1016/j.jconrel.2014.09.001
58. Li Z, Rana TM. Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discov (2014) 13:622-38. doi:10.1038/nrd4359
59. Kortylewski M, Nechaev S. How to train your dragon: targeted delivery of microRNA to cancer cells in vivo. Mol Ther (2014) 22:1070-1. doi:10.1038/mt.2014.73
60. Kwekkeboom RF, Lei Z, Doevendans PA, Musters RJ, Sluijter JP. Targeted delivery of miRNA therapeutics for cardiovascular diseases: opportunities and challenges. Clin Sci (2014) 127:351-65. doi:10.1042/CS20140005
61. Krützfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature (2005) 438:685-9. doi:10.1038/nature04303
62. Obad S, dos Santos CO, Petri A, Heidenblad M, Broom O, Ruse C, et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet (2011) 43:371-8. doi:10.1038/ng.786
63. Lennox KA, Behlke MA. Chemical modification and design of anti-miRNA oligonucleotides. Gene Ther (2011) 18:1111-20. doi:10.1038/gt.2011.100
64. Stenvang J, Petri A, Lindow M, Obad S, Kauppinen S. Inhibition of microRNA function by antimiR oligonucleotides. Silence (2012) 3:1. doi:10.1186/1758-907X-3-1
65. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov (2010) 9:775-89. doi:10.1038/nrd3179
66. Choi YS, Lee JY, Suh JS, Kwon YM, Lee SJ, Chung JK, et al. The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine. Biomaterials (2010) 31:1429-43. doi:10.1016/j.biomaterials.2009.11.001
67. Park TG, Jeong JH, Kim SW. Current status of polymeric gene delivery systems. Adv Drug Deliv Rev (2006) 58:467-86. doi:10.1016/j.addr.2006.03.007
68. Tros de Ilarduya C, Sun Y, Duzgunes N. Gene delivery by lipoplexes and polyplexes. Eur J Pharm Sci (2010) 40:159-70. doi:10.1016/j.ejps.2010.03.019
69. Ben-Shushan D, Markovsky E, Gibori H, Tiram G, Scomparin A, Satchi-Fainaro R. Overcoming obstacles in microRNA delivery towards improved cancer therapy. Drug Deliv Transl Res (2014) 4:38-49. doi:10.1007/s13346-013-0160-0
70. Ren Y, Kang CS, Yuan XB, Zhou X, Xu P, Han L, et al. Co-delivery of as-miR-21 and 5-FU by poly(amidoamine) dendrimer attenuates human glioma cell growth in vitro. J Biomater Sci Polym Ed (2010) 21:303-14. doi:10.1163/156856209X415828
71. Zhang Y, Wang Z, Gemeinhart RA. Progress in microRNA delivery. J Control Release (2013) 172:962-74. doi:10.1016/j.jconrel.2013.09.015
72. Chauhan AS, Jain NK, Diwan PV. Pre-clinical and behavioural toxicity profile of PAMAM dendrimers in mice. Proc R Soc A (2010) 466(2117):1535-50. doi:10.1098/rspa.2009.0448
73. Zhang Y, Satterlee A, Huang L. In vivo gene delivery by nonviral vectors: overcoming hurdles? Mol Ther (2012) 20:1298-304. doi:10.1038/mt.2012.79
74. Cubillos-Ruiz JR, Baird JR, Tesone AJ, Rutkowski MR, Scarlett UK, Camposeco-Jacobs AL, et al. Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer. Cancer Res (2012) 72:1683-93. doi:10.1158/0008-5472.CAN-11-3160
75. Ando H, Asai T, Koide H, Okamoto A, Maeda N, Tomita K, et al. Advanced cancer therapy by integrative antitumor actions via systemic administration of miR-499. J Control Release (2014) 181:32-9. doi:10.1016/j.jconrel.2014.02.019
76. Liu XQ, Song WJ, Sun TM, Zhang PZ, Wang J. Targeted delivery of antisense inhibitor of miRNA for antiangiogenesis therapy using cRGD-functionalized nanoparticles. Mol Pharm (2011) 8:250-9. doi:10.1021/mp100315q
77. Anand S, Majeti BK, Acevedo LM, Murphy EA, Mukthavaram R, Scheppke L, et al. MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med (2010) 16:909-14. doi:10.1038/nm.2186
78. Chou ST, Leng Q, Scaria P, Kahn JD, Tricoli LJ, Woodle M, et al. Surface-modified HK:siRNA nanoplexes with enhanced pharmacokinetics and tumor growth inhibition. Biomacromolecules (2013) 14:752-60. doi:10.1021/bm3018356